[
  {
    "id": "doc_001",
    "name": "Protocol_BIIB122-DNL151_LIGHTHOUSE_Amendment_v4.0.pdf",
    "description": "Amendment 4 to the Phase 3 LIGHTHOUSE study protocol for Parkinson's disease. This version incorporates updated guidance on CSF biomarker sample collection and adjusts the statistical analysis plan based on recommendations from the Data Monitoring Committee.",
    "modified": "2024-05-15T14:30:00Z",
    "version": "4.0",
    "type": "pdf"
  },
  {
    "id": "doc_002",
    "name": "DNL310_Investigator_Brochure_Ed9_2024.pdf",
    "description": "9th Edition of the Investigator's Brochure for tividenofusp alfa (DNL310), summarizing all current non-clinical and clinical data, including pharmacology, toxicology, and integrated safety information from the Phase 1/2 study and long-term extension in patients with Hunter Syndrome (MPS II).",
    "modified": "2024-04-22T11:00:00Z",
    "version": "9.0",
    "type": "pdf"
  },
  {
    "id": "doc_003",
    "name": "CSR_DNL310-001_Final_Report.docx",
    "description": "Final Clinical Study Report for study DNL310-001, a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of tividenofusp alfa in patients with Hunter syndrome. This report forms a core component of the BLA submission.",
    "modified": "2024-02-10T18:45:00Z",
    "version": "1.0 Final",
    "type": "docx"
  },
  {
    "id": "doc_004",
    "name": "Master_ICF_Template_DNL126-001_Pediatric_v2.1.docx",
    "description": "Master Informed Consent Form (ICF) and Assent Form template for study DNL126-001 in pediatric patients with Sanfilippo syndrome (MPS IIIA). Version 2.1 includes updated language on genetic data privacy and long-term follow-up procedures.",
    "modified": "2024-06-05T09:12:00Z",
    "version": "2.1",
    "type": "docx"
  },
  {
    "id": "doc_005",
    "name": "DSUR_DNL343-ALS_Annual_Report_2023.pdf",
    "description": "Annual Development Safety Update Report (DSUR) for the DNL343 program in ALS. This report provides a comprehensive analysis of safety data from the reporting period, including an evaluation of the negative efficacy readout and ongoing safety monitoring.",
    "modified": "2024-03-28T16:20:00Z",
    "version": "2023.v1",
    "type": "pdf"
  },
  {
    "id": "doc_006",
    "name": "Denali-Takeda_JSC_Meeting_Minutes_Q1_2024.pdf",
    "description": "Meeting minutes from the Q1 2024 Joint Steering Committee (JSC) for the TAK-594/DNL593 collaboration. Key discussion points include enrollment progress for the FTD-GRN study, review of preclinical data, and alignment on regulatory strategy.",
    "modified": "2024-04-18T10:05:00Z",
    "version": "1.0",
    "type": "pdf"
  },
  {
    "id": "doc_007",
    "name": "DNL919-AD_SIV_Presentation_Template_US_v1.2.pptx",
    "description": "Site Initiation Visit (SIV) presentation template for US sites participating in the Phase 1b study of DNL919 in Alzheimer's disease. This deck provides investigators and site staff with a comprehensive overview of the protocol, study procedures, and use of the Transport Vehicle platform.",
    "modified": "2024-05-29T13:00:00Z",
    "version": "1.2",
    "type": "pptx"
  },
  {
    "id": "doc_008",
    "name": "BLA_21XXXX_DNL310_Module_3_CMC_Overview.pdf",
    "description": "CTD Module 3 (Quality) overview for the Biologics License Application (BLA) for tividenofusp alfa (DNL310). This document details the Chemistry, Manufacturing, and Controls (CMC) for the drug substance and product, including information from the Salt Lake City facility.",
    "modified": "2024-01-15T20:00:00Z",
    "version": "1.0",
    "type": "pdf"
  },
  {
    "id": "doc_009",
    "name": "ROPAD_Study_Site_Newsletter_Q2_2024.pdf",
    "description": "Quarterly newsletter for the ~48 global sites participating in the ROPAD Parkinson's genetics and observational study. This issue highlights enrollment milestones and provides an update on how ROPAD data is helping to identify candidates for Denali's interventional trials.",
    "modified": "2024-06-12T15:00:00Z",
    "version": "Q2 2024",
    "type": "pdf"
  },
  {
    "id": "doc_010",
    "name": "Patient_Advocacy_Communication_DNL310_BLA_Update.pdf",
    "description": "A communication document for patient advocacy groups and the broader Hunter syndrome community, providing an update on the FDA's acceptance of the BLA for tividenofusp alfa (DNL310) under Priority Review and outlining anticipated timelines.",
    "modified": "2024-03-04T12:30:00Z",
    "version": "1.0",
    "type": "pdf"
  }
]